Holen Sie sich die Stockscreener-App
0.3005
0.67%
0.0005
Schlusskurs vom Vortag:
$0.30
Offen:
$0.3
24-Stunden-Volumen:
6.29M
Relative Volume:
0.73
Marktkapitalisierung:
$16.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.36M
KGV:
-0.4481
EPS:
-0.6706
Netto-Cashflow:
$-23.09M
1W Leistung:
+42.45%
1M Leistung:
-61.05%
6M Leistung:
-55.92%
1J Leistung:
-74.41%
1-Tages-Spanne:
$0.2964
$0.317
1-Wochen-Bereich:
$0.207
$0.651
52-Wochen-Spanne:
$0.1952
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corp
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.3034 | 12.31M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
520.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.46 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
998.39 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.04 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.72 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corp Aktie (PDSB) Neueste Nachrichten
Curious about the most active stocks on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
PDS Biotech soars as it announces up to $22.55 million financing - The Pharma Letter
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure - Quiver Quantitative
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC - AllSci
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - Benzinga
PDS Biotechnology Announces PIPE Financing and Strategic Alignment - TipRanks
PDS Biotech raises up to $22.55M led by Nant Capital - Investing.com Canada
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks - marketscreener.com
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
symbol__ Stock Quote Price and Forecast - cnn.com
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors - TipRanks
PDS Biotech’s Lender Gets 100% of New Non-ATM Equity Cash - TechStock²
PDS Biotechnology Amends $6 Million Promissory Note, Tightening Repayment With YA II PN - TradingView
PDS Biotechnology (Nasdaq: PDSB) changes terms on a $6M loan - Stock Titan
Stephan Toutain removed as COO at PDS Biotechnology - TradingView
PDS Biotechnology Corp (NASDAQ: PDSB) Share Price, PDSB Stock News, PDSB Share Price & Updates - Kalkine
Form 8K PDS Biotechnology Corp For: 19 August By Investing.com - Investing.com Nigeria
PDS Biotechnology announces CFO resignation and interim appointments - Investing.com
PDS Biotechnology CFO Lars Boesgaard to Resign; Janetta Trochimiuk and Frank Bedu-Addo Appointed Interim Officers - TradingView
PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs - Stock Titan
Weekly Recap: PDS0301 Phase 2 results and Q2 adjusted loss $0.18 - TradingView
PDS Biotechnology shareholders approve charter amendment and director elections - Investing.com
Form 8K PDS Biotechnology Corp For: 14 August By Investing.com - Investing.com Nigeria
PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors - Stock Titan
PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M - Stock Titan
PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PDS Biotechnology Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Form 8K PDS Biotechnology Corp For: 13 August By Investing.com - Investing.com South Africa
PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301 - TradingView
PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss - Quiver Quantitative
PDS Biotech Reports Second Quarter 2026 Financial Results - The Manila Times
PDS Biotechnology: Q2 Earnings Snapshot - Barchart.com
PDS Biotech Prioritizes PDS0301 After 71% Response Rate In Colorectal Cancer And Discontinues PDS0101 Phase 3 Trial - Pulse 2.0
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.34% - Investing.com
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial By Investing.com - Investing.com South Africa
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga
Form 8K PDS Biotechnology Corp For: 11 August By Investing.com - Investing.com Nigeria
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 - manilatimes.net
PDS Biotechnology prioritizes PDS0301 after Phase 2 mCRC data, halts internal PDS0101 Phase 3 spend - TradingView
PDS Biotechnology shifts focus to PDS0301, halts PDS0101 trial - Investing.com
PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial - Quiver Quantitative
PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp expected to post a loss of 13 cents a shareEarnings Preview - TradingView
PDS Biotechnology Corp (PDSB) Stock News Today - TradingKey
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFull Year Guidance - vinanet.vn
PDS Biotechnology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
PDSB Q1 2026 Earnings: Narrower-than-Expected Loss as Immuno-Oncology Pipeline AdvancesMargin Expansion Trends - vinanet.vn
PDSB|PDS Biotechnology Corp|Price:0.699|Chg%:+0.017 - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der Pds Biotechnology Corp-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):